Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,465 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT07241039 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors | recruiting | Phase 1 | 220 | AbbVieINDUSTRY | 4 | Aug 19, 2026 |
| clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT06733441 | A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma | active not recruiting | Phase 1 | 50 | Treeline Biosciences, Inc.INDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT00750841 | Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | active not recruiting | Phase 1 | 64 | AstraZenecaINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04774718 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 11 | Aug 14, 2026 | clinicaltrials |
| NCT06743555 | Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study(SAVED LUNG) | not yet recruiting | Phase 1 | 14 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07304154 | A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases | recruiting | Phase 1 | 52 | Kite, A Gilead CompanyINDUSTRY | 3 | Aug 14, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06384352 | Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 500 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 4 | Aug 13, 2026 | clinicaltrials |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | completed | Phase 1 | 134 | AbbVieINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT03391778 | Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | enrolling by invitation | Phase 1 | 250 | USWM CT, LLCINDUSTRY | 8 | Aug 11, 2026 | clinicaltrials |
| NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | active not recruiting | Phase 1 / Phase 2 | 61 | MedImmune LLCINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT06666348 | Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV) | recruiting | Phase 1 / Phase 2 | 50 | St. Justine's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05382325 | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | active not recruiting | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT06067841 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 140 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | active not recruiting | Phase 1 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT06542250 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.(TITANium) | recruiting | Phase 1 / Phase 2 | 174 | AstraZenecaINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05753501 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | active not recruiting | Phase 1 | 135 | AbbVieINDUSTRY | 9 | Aug 6, 2026 | clinicaltrials |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 52 | Jennerex BiotherapeuticsINDUSTRY | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06706076 | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations(SOLARA) | recruiting | Phase 1 / Phase 2 | 675 | BlossomHill TherapeuticsINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT03843359 | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | terminated | Phase 1 | 97 | GlaxoSmithKlineINDUSTRY | 8 | Aug 3, 2026 | clinicaltrials |
| NCT04556773 | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer(DB-08) | active not recruiting | Phase 1 | 138 | AstraZenecaINDUSTRY | 10 | Aug 3, 2026 | clinicaltrials |
| NCT05687110 | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT03854474 | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03598244 | Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | active not recruiting | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2026 | clinicaltrials |
| NCT05464030 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | active not recruiting | Phase 1 | 220 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jul 30, 2026 | clinicaltrials |
| NCT07094113 | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 434 | AmgenINDUSTRY | 14 | Jul 30, 2026 | clinicaltrials |
| NCT03075696 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 940 | Hoffmann-La RocheINDUSTRY | 13 | Jul 29, 2026 | clinicaltrials |
| NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | terminated | Phase 1 | 17 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05365659 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | recruiting | Phase 1 | 140 | Iksuda Therapeutics Ltd.INDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT06764771 | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | recruiting | Phase 1 | 437 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT04058756 | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | active not recruiting | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 17 | Jul 28, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials